Objective:To evaluate systematically the clinical efficacy and safety of puerarin injection for the adjuvant therapy of acute anterior wall myocardial infarction. Method:Randomized controlled trials (RCTs) about puerarin injection for acute anterior wall myocardial infarction were searched systemically and comprehensively. Two reviewers assessed the quality of the included studies by the Cochrane risk of bias

and extracted the information from them. Meta-analysis was conducted with the software Review Manager 5.2. Result:A total of 6 studies with 354 participants were included

and the quality of the studies was relatively low. There was only one study to generate random sequence by drawing lots. In the meta-analysis

the results of puerarin group were significantly superior to the west conventional therapy group in decreasing the score of QRS[MD=-1.69

95%CI (-2.07

-1.32)

P<0.000 01]

reducing the infarct size[MD=-9.46

95%CI(-11.37

-7.55)

P<0.000 01]

increasing the ejection fraction left ventricular ejection fraction(LVEF)[MD=12.18

95%CI (2.97

21.39)

P=0.010] and erythrocyte superoxide dismutase(SOD) values[MD=611.47

95%CI (464.80

758.14)

P<0.000 01]

and reducing mortality rate

and so on. And there was only 1 adverse drug reaction (ADR) reported

more quality studies should be included. Conclusion:Comparing with the conventional therapy of the control group used for treating acute anterior wall myocardial infarction

puerarin injection combined with the conventional therapy was relatively effective and safety

which was based on the systematic review.